AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03409900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLB
Description: The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
Study NCT00985517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CERE-120: Adeno-Associated Virus Delivery of Neurturin
Study NCT00985517 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Study NCT01471509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water, glucose with or without amino acid
Description: 240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
Study NCT01471509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water, glucose with or without amino acid
Description: 240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
Study NCT00503451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT03909113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino acid based formula
Description: amino acid based formula
Study NCT03785899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPOCnew
Description: SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on.
Study NCT03785899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 8s.
Study NCT03785899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 8s.
Study NCT03785899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPOCold
Description: SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on.
Study NCT03785899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 2s.
Study NCT03785899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 2s.
Study NCT03147300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current routine practice
Description: Current routine practice for the primary care management of LBP
Study NCT02645773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative laser
Description: non-abaltive laser pre, immediate and post wounding
Study NCT00397137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circular stapled anopexy
Description: Patients receiving stapled anopexy to treat haemorrhoids
Study NCT00397137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed diathermy haemorrhoidectomy
Description: Conventional haemorrhoidectomy as described by Ferguson method
Study NCT03666208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Coated Balloon
Description: Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution.
Study NCT02452125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine chewing gum
Study NCT02927899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02927899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato-Soy Juice
Description: Receive tomato-soy beverages with or without varying levels of arugula seed powder
Study NCT02456298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard FA+FCT
Description: Standard Functional Analysis and Functional Communication Training
Study NCT02456298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pragmatic FA+FCT
Description: Pragmatic Functional Analysis and Functional Communication Training
Study NCT00726388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIC075V (intravenous diclofenac sodium)
Description: multiple doses up to 5 days
Study NCT02941432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Black tea compress treatment
Description: Wet compresses with black tea applied 4-5 times daily to the face for 6 days
Study NCT01011049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal
Study NCT01011049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular
Study NCT02312622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Irinotecan
Description: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
Study NCT01297699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (RoActemra®)
Description: Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
Study NCT01297699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile 0.9% Sodium Chloride
Description: Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
Study NCT04010383 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: virtual reality perimeter
Description: Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
Study NCT04441996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Description: Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
Study NCT04441996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
Study NCT01053897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBT009
Description: Intradermal Injection following surgery
Study NCT01053897 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Injection following surgery
Study NCT02001389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6308
Description: Arms 1, 2, 3, 4
Study NCT02125097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barrel™ Vascular Reconstruction Device (VRD)
Description: Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
Study NCT03849521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Enhanced carotid calcification presented by UTE MR.
Study NCT03147300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation of the BetterBack
Description: The multifaceted intervention is composed of the following:~1. Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~2. Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~3. Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~4. Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians.
Study NCT04489849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: apixaban 2.5mg BID for 3 months in experimental group
Study NCT04489849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Medication other than anticoagulation
Study NCT04398186 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anogenital distance measurement
Description: Measurements of AGD and perineal muscle strength
Study NCT03567512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking hygiene intervention
Description: The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
Study NCT03567512 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes).
Study NCT03838237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiological evaluation
Description: Baseline evaluation~* FAbry STabilization indEX (FASTEX)~* 12 leads ECG~* Blood samples for microRNA, TnT HS and NT-proBNP dosages~* 2D echocardiogram~* Cardio-pulmonary test~* Contrast-enhanced CMR including:~  * Cine images~ * T2 mapping sequences~ * T1 mapping sequences before and 15' after contrast medium administration~ * Late Gadolinium Enhancement (LGE) imaging~ * Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated
Study NCT02686658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 20 mg/mL solution for intravitreal (IVT) injection
Study NCT02686658 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
Study NCT02686658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
Study NCT01046032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
Study NCT01046032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
Study NCT00825656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinol or Sinol-M nasal spray
Description: One spray in each nostril up to a maximum of 12 times / day on an as needed basis
Study NCT00825656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinol or Sinol-M nasal spray
Description: One spray in each nostril up to a maximum of 12 times / day on an as needed basis
Study NCT02096068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dexdor®)
Description: Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
Study NCT02096068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
Study NCT00821223 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification and SICS
Description: SICS with rigid IOL implantation Phaco with foldable IOL implantation
Study NCT00821223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual small incision surgery
Study NCT00821223 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification
Description: cataract surgery
Study NCT02978391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UI-EWD Hemostatic system
Description: Adhesive endoscopic hemostats, powder type
Study NCT02978391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine endoscopic injection (conventional therapy)
Description: endoscopic submucosal injection of epinephrine (1: 10,000)
Study NCT03679286 — intervention group
Intervention type: DEVICE
Intervention: PCM and ROTEM
Description: Test of blood sample by both PCM and ROTEM
Study NCT02718248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHESS Mobile Health smart phone application
Description: A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
Study NCT02718248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Face to face problem solving therapy every week for six weeks.
Study NCT01238718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1.5 mg/kg intravenously
Study NCT01238718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study NCT00745511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORA102 and Avastin
Description: treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
Study NCT00745511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avastin
Description: treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
Study NCT03014713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dezocine
Description: Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
Study NCT03014713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
Study NCT03014713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flubiprofen
Description: Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
Study NCT03014713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flubiprofen
Description: Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
Study NCT03014713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
Study NCT02436031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time
Study NCT02436031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time
Study NCT02436031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study NCT02436031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study NCT04336813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audience Response system
Description: In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
Study NCT04336813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audience Response system
Description: In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
Study NCT01886742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Group
Description: The standard dose of Cefazolin will be administered intravenously.
Study NCT01886742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weight Based Group
Description: The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
Study NCT03047096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: intra-Articular injection
Study NCT03047096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid and corticosteroids
Description: intra-Articular injection
Study NCT03576534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of prebypass ultrafiltration (PBUF)
Description: In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
Study NCT01492725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-arterial Clot Retrieval with Solitaire device
Description: Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
Study NCT01492725 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tissue plasminogen activator (tPA)
Description: Standard care IV tPA therapy administered as per registered product information
Study NCT03499275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NMES
Description: Neuromuscular electrical stimulation to the quadriceps muscle
Study NCT03499275 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NMES
Description: Sham neuromuscular electrical stimulation to the quadriceps muscle
Study NCT03499275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise programme
Description: Home exercise programme. Both arms of the trial receive this intervention.
Study NCT03499275 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home exercise programme
Description: Home exercise programme. Both arms of the trial receive this intervention.
Study NCT03499275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathlessness advice
Description: Breathlessness advice. Both arms of the trial receive this intervention.
Study NCT03499275 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breathlessness advice
Description: Breathlessness advice. Both arms of the trial receive this intervention.